June 5, 2012

Malignant hyperthermia: A crisis response plan

By: OR Manager

Malignant hyperthermia (MH) is a genetic skeletal muscle disorder that is incited by anesthesia drugs including succinlycholine and inhaled anesthetic agents (Gurunluoglu et al, 2009; Hopkins, 2011; Kim et al, 2011). The disorder is particularly dangerous because it rapidly develops into a hypermetabolic state resulting in hyperpyrexia, tachycardia, and intense and unrelenting muscle contraction as well as alterations in electrolyte and acid-base balance (Kim et al, 2011).

Welcome to OR Manager, your source of information and insight into the clinical and business management of the surgical suite. This article is only available to OR Manager subscribers. To read this article, and gain access to all OR Manager resources, please log in below:

  Join the OR Manager Community! OR Manager is the trusted source for perioperative leaders, providing critical information, analysis, and best practices for management of the surgical suite. Join as a Premium Subscriber to access all articles online including archives, the digital issue of OR Manager each month, eligibility for CE contact hours, registration discounts on conferences and more. We also offer a complimentary Plus subscription to those who qualify and a complimentary Community subscription.

Explore Subscription Options

Please contact our Customer Service Team if you are unable to log in at [email protected] or 1-888-707-5814.

Join our community

Learn More
Video Spotlight
Live chat by BoldChat